As digital health technologies proliferate, the US Food and Drug Administration (FDA) is taking a closer look at how they can capture information about a person’s health outside of a clinical setting.
For Parkinson’s disease, a handful of wearable technologies have already been cleared to track symptoms.
According to leading data and analytics company GlobalData, the market for neurological devices was valued at $12.5bn in 2023 and is expected to grow by a compound annual growth rate of 4.60% to reach $20.9bn by 2033.
